Visitors Now:
Total Visits:
Total Stories:
Profile image
Story Views

Now:
Last Hour:
Last 24 Hours:
Total:

Human Papillomavirus (HPV) Associated Cancer Treatment Pipeline Review H2 2016

Friday, October 14, 2016 3:52
% of readers think this story is Fact. Add your two cents.

(Before It's News)

Summary

‘Human papillomavirus (HPV) Associated Cancer – Pipeline Review, H2 2016’, provides an overview of the Human papillomavirus (HPV) Associated Cancer pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Human papillomavirus (HPV) Associated Cancer, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Human papillomavirus (HPV) Associated Cancer and features dormant and discontinued projects.

Request a sample report @ https://www.wiseguyreports.com/sample-request/685904-human-papillomavirus-hpv-associated-cancer-pipeline-review-h2-2016

Report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Scope

- The report provides a snapshot of the global therapeutic landscape of Human papillomavirus (HPV) Associated Cancer 
- The report reviews pipeline therapeutics for Human papillomavirus (HPV) Associated Cancer by companies and universities/research institutes based on information derived from company and industry-specific sources 
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages 
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities 
- The report reviews key players involved Human papillomavirus (HPV) Associated Cancer therapeutics and enlists all their major and minor projects 
- The report assesses Human papillomavirus (HPV) Associated Cancer therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type 
- The report summarizes all the dormant and discontinued pipeline projects 
- The report reviews latest news related to pipeline therapeutics for Human papillomavirus (HPV) Associated Cancer

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies 
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage 
- Identify and understand important and diverse types of therapeutics under development for Human papillomavirus (HPV) Associated Cancer 
- Identify potential new clients or partners in the target demographic 
- Develop strategic initiatives by understanding the focus areas of leading companies 
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics 
- Devise corrective measures for pipeline projects by understanding Human papillomavirus (HPV) Associated Cancer pipeline depth and focus of Indication therapeutics 
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope 
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Make an enquiry before buying this Report @ https://www.wiseguyreports.com/enquiry/685904-human-papillomavirus-hpv-associated-cancer-pipeline-review-h2-2016

Key points in table of content

Table of Contents 2 
List of Tables 6 
List of Figures 7 
Introduction 8 
Global Markets Direct Report Coverage 8 
Human Papillomavirus (HPV) Associated Cancer Overview 9 
Therapeutics Development 10 
Pipeline Products for Human Papillomavirus (HPV) Associated Cancer – Overview 10 
Pipeline Products for Human Papillomavirus (HPV) Associated Cancer – Comparative Analysis 11 
Human Papillomavirus (HPV) Associated Cancer – Therapeutics under Development by Companies 12 
Human Papillomavirus (HPV) Associated Cancer – Therapeutics under Investigation by Universities/Institutes 15 
Human Papillomavirus (HPV) Associated Cancer – Pipeline Products Glance 16 
Late Stage Products 16 
Clinical Stage Products 17 
Early Stage Products 18 
Human Papillomavirus (HPV) Associated Cancer – Products under Development by Companies 19 
Human Papillomavirus (HPV) Associated Cancer – Products under Investigation by Universities/Institutes 22 
Human Papillomavirus (HPV) Associated Cancer – Companies Involved in Therapeutics Development 23 
Admedus Ltd 23 
Advaxis, Inc. 24 
Antigen Express, Inc. 25 
Bionor Pharma ASA 26 
BioNTech AG 27 
Cancer Research Technology Limited 28 
Cell Medica Limited 29 
Etubics Corporation 30 
EyeGene, Inc. 31 
Formune S.L. 32 
Genexine, Inc. 33 
Genticel S.A. 34 
iBio, Inc. 35 
Immunovaccine, Inc. 36 
Inovio Pharmaceuticals, Inc. 37 
Inthera Bioscience AG 38 
Johnson & Johnson 39 
Karyopharm Therapeutics, Inc. 40 
Kite Pharma, Inc. 41 
MedImmune, LLC 42 
Novartis AG 43 
Onconova Therapeutics, Inc. 44 
Oryx GmbH & Co. KG 45 
Profectus BioSciences, Inc. 46 
Selecta Biosciences, Inc. 47 
Shantha Biotechnics Limited 48 
Sirnaomics, Inc. 49 
Theravectys SA 50 
THEVAX Genetics Vaccine USA Inc 51 
Tomegavax, Inc. 52 
Transgene SA 53 
UbiVac, LLC 54 
Vaccibody AS 55 
Vault Pharma Inc. 56 
Virometix AG 57 
ViroStatics srl 58 
VLPbio 59 
Human Papillomavirus (HPV) Associated Cancer – Therapeutics Assessment 60 
Assessment by Monotherapy Products 60 
Assessment by Target 61 
Assessment by Mechanism of Action 63 
Assessment by Route of Administration 65 
Assessment by Molecule Type 67 
Drug Profiles 69 
ABI-1968 – Drug Profile 69 
AEH-10p – Drug Profile 70 
alpelisib – Drug Profile 71 
Antibodies to Target E6 for HPV Associated Cancer – Drug Profile 74 
Antibodies to Target E7 for HPV Associated Cancer – Drug Profile 75 
BVAC-C – Drug Profile 76 
Cellular Immunotherapy for HPV Associated Cancers – Drug Profile 77 
Cellular Immunotherapy to Target HPV-16 E6 Protein for Cancer – Drug Profile 78 
Cellular Immunotherapy to Target HPV-16 E7 Protein for Head and Neck Cancer and Cervical Cancer – Drug Profile 80 
CerviVax – Drug Profile 82 
CMD-004 – Drug Profile 83 
DPV-001 – Drug Profile 84 
DPXE-7 – Drug Profile 86 
EDA-HPVE7 – Drug Profile 87 
EG-HPV – Drug Profile 88 
Enzymes to Inhibit HPV E7 for Human Papillomavirus Related Cervical Cancer – Drug Profile 89 
ETBX-041 – Drug Profile 90 
GTL-001 – Drug Profile 91 
GTL-002 – Drug Profile 94 
GX-188E – Drug Profile 95 
human papillomavirus (7-valent) vaccine – Drug Profile 97 
human papillomavirus [Serotype 16] vaccine – Drug Profile 98 
human papillomavirus [serotypes 16] vaccine – Drug Profile 99 
human papillomavirus vaccine – Drug Profile 100 
human papillomavirus vaccine – Drug Profile 101 
human papillomavirus vaccine – Drug Profile 102 
human papillomavirus vaccine [types 6, 11, 16, 18] biosimilar – Drug Profile 103 
INO-3106 – Drug Profile 104 
INO-3112 – Drug Profile 105 
Lm-LLO-ISG15 – Drug Profile 107 
LN-145 – Drug Profile 109 
Monoclonal Antibody to Target E6 and E7 Proteins for Oncology – Drug Profile 111 
NIT-02 – Drug Profile 112 
NP-001 – Drug Profile 113 
PVX-01 – Drug Profile 114 
Recombinant Vector Vaccine to Target E7 for HPV Associated Cancers – Drug Profile 115 
Recombinant Vector Vaccine to Target E7 for HPV Associated Cervical Intraepithelial Neoplasia – Drug Profile 116 
rigosertib sodium – Drug Profile 117 
sdCMV-002 – Drug Profile 128 
SEL-701 – Drug Profile 129 
Small Molecule to Inhibit CDK4, CDK6 and CDK9 for HPV Associated Cancers – Drug Profile 130 
Small Molecules for Solid Tumors and HPV Associated Cancer – Drug Profile 131 
STP-909 – Drug Profile 132 
Subunit Vaccine for HPV Associated Cervical Cancer – Drug Profile 133 
Synthetic Peptide to Inhibit HPV E6 Protein for HPV Associated Cancer – Drug Profile 134 
TA-CIN – Drug Profile 135 
TG-4001 – Drug Profile 136 
TVGV-1 – Drug Profile 138 
Vacc-HPV – Drug Profile 139 
Vaccine for HIV and HPV Associated Cancer – Drug Profile 140 
Vaccine for HPV Associated Cancer – Drug Profile 141 
Vaccine for HPV Associated Cancers – Drug Profile 142 
Vaccine for HPV Associated Cervical Cancer – Drug Profile 143 
Vaccine for HPV Associated Cervical Cancer – Drug Profile 144 
Vaccine for HPV Associated Cervical Cancer – Drug Profile 145 
Vaccine for HPV Associated Skin Cancer – Drug Profile 146 
Vaccine for Human papillomavirus Associated Cervical Cancer – Drug Profile 147 
VB-1016 – Drug Profile 148 
verdinexor – Drug Profile 150 
VGX-3100 – Drug Profile 151 
Vicoryx – Drug Profile 154 
VMT-2 – Drug Profile 155 
VPI-241 – Drug Profile 156 
Vvax-001 – Drug Profile 157 
Human Papillomavirus (HPV) Associated Cancer – Dormant Projects 158 
Human Papillomavirus (HPV) Associated Cancer – Product Development Milestones 160 
Featured News & Press Releases 160 
Appendix 167 
Methodology 167 
Coverage 167 
Secondary Research 167 
Primary Research 167 
Expert Panel Validation 167 
Contact Us 167 
Disclaimer 168

List of Tables 
Number of Products under Development for Human Papillomavirus (HPV) Associated Cancer, H2 2016 14 
Number of Products under Development for Human Papillomavirus (HPV) Associated Cancer – Comparative Analysis, H2 2016 15 
Number of Products under Development by Companies, H2 2016 16 
Number of Products under Development by Companies, H2 2016 (Contd..1) 17 
Number of Products under Development by Companies, H2 2016 (Contd..2) 18 
Number of Products under Investigation by Universities/Institutes, H2 2016 19 
Comparative Analysis by Late Stage Development, H2 2016 20 
Comparative Analysis by Clinical Stage Development, H2 2016 21 
Comparative Analysis by Early Stage Development, H2 2016 22 
Products under Development by Companies, H2 2016 23 
Products under Development by Companies, H2 2016 (Contd..1) 24 
Products under Development by Companies, H2 2016 (Contd..2) 25 
Products under Investigation by Universities/Institutes, H2 2016 26 
Human Papillomavirus (HPV) Associated Cancer – Pipeline by Admedus Ltd, H2 2016 27 
Human Papillomavirus (HPV) Associated Cancer – Pipeline by Advaxis, Inc., H2 2016 28 
Human Papillomavirus (HPV) Associated Cancer – Pipeline by Antigen Express, Inc., H2 2016 29 
Human Papillomavirus (HPV) Associated Cancer – Pipeline by Bionor Pharma ASA, H2 2016 30 
Human Papillomavirus (HPV) Associated Cancer – Pipeline by BioNTech AG, H2 2016 31 
Human Papillomavirus (HPV) Associated Cancer – Pipeline by Cancer Research Technology Limited, H2 2016 32
Human Papillomavirus (HPV) Associated Cancer – Pipeline by Cell Medica Limited, H2 2016 33 
Human Papillomavirus (HPV) Associated Cancer – Pipeline by Etubics Corporation, H2 2016 34 
Human Papillomavirus (HPV) Associated Cancer – Pipeline by EyeGene, Inc., H2 2016 35 
Human Papillomavirus (HPV) Associated Cancer – Pipeline by Formune S.L., H2 2016 36 
Human Papillomavirus (HPV) Associated Cancer – Pipeline by Genexine, Inc., H2 2016 37 
Human Papillomavirus (HPV) Associated Cancer – Pipeline by Genticel S.A., H2 2016 38 
Human Papillomavirus (HPV) Associated Cancer – Pipeline by iBio, Inc., H2 2016 39 
Human Papillomavirus (HPV) Associated Cancer – Pipeline by Immunovaccine, Inc., H2 2016 40 
Human Papillomavirus (HPV) Associated Cancer – Pipeline by Inovio Pharmaceuticals, Inc., H2 2016 41 
Human Papillomavirus (HPV) Associated Cancer – Pipeline by Inthera Bioscience AG, H2 2016 42 
Human Papillomavirus (HPV) Associated Cancer – Pipeline by Johnson & Johnson, H2 2016 43 
Human Papillomavirus (HPV) Associated Cancer – Pipeline by Karyopharm Therapeutics, Inc., H2 2016 44 
Human Papillomavirus (HPV) Associated Cancer – Pipeline by Kite Pharma, Inc., H2 2016 45 
Human Papillomavirus (HPV) Associated Cancer – Pipeline by MedImmune, LLC, H2 2016 46 
Human Papillomavirus (HPV) Associated Cancer – Pipeline by Novartis AG, H2 2016 47 
Human Papillomavirus (HPV) Associated Cancer – Pipeline by Onconova Therapeutics, Inc., H2 2016 48 
Human Papillomavirus (HPV) Associated Cancer – Pipeline by Oryx GmbH & Co. KG, H2 2016 49 
Human Papillomavirus (HPV) Associated Cancer – Pipeline by Profectus BioSciences, Inc., H2 2016 50 
Human Papillomavirus (HPV) Associated Cancer – Pipeline by Selecta Biosciences, Inc., H2 2016 51 
Human Papillomavirus (HPV) Associated Cancer – Pipeline by Shantha Biotechnics Limited, H2 2016 52 
Human Papillomavirus (HPV) Associated Cancer – Pipeline by Sirnaomics, Inc., H2 2016 53 
Human Papillomavirus (HPV) Associated Cancer – Pipeline by Theravectys SA, H2 2016 54 
Human Papillomavirus (HPV) Associated Cancer – Pipeline by THEVAX Genetics Vaccine USA Inc, H2 2016 55 
Human Papillomavirus (HPV) Associated Cancer – Pipeline by Tomegavax, Inc., H2 2016 56 
Human Papillomavirus (HPV) Associated Cancer – Pipeline by Transgene SA, H2 2016 57 
Human Papillomavirus (HPV) Associated Cancer – Pipeline by UbiVac, LLC, H2 2016 58 
Human Papillomavirus (HPV) Associated Cancer – Pipeline by Vaccibody AS, H2 2016 59 
Human Papillomavirus (HPV) Associated Cancer – Pipeline by Vault Pharma Inc., H2 2016 60 
Human Papillomavirus (HPV) Associated Cancer – Pipeline by Virometix AG, H2 2016 61 
Human Papillomavirus (HPV) Associated Cancer – Pipeline by ViroStatics srl, H2 2016 62 
Human Papillomavirus (HPV) Associated Cancer – Pipeline by VLPbio, H2 2016 63 
Assessment by Monotherapy Products, H2 2016 64 
Number of Products by Stage and Target, H2 2016 66 
Number of Products by Stage and Mechanism of Action, H2 2016 68 
Number of Products by Stage and Route of Administration, H2 2016 70 
Number of Products by Stage and Molecule Type, H2 2016 72 
Human Papillomavirus (HPV) Associated Cancer – Dormant Projects, H2 2016 162 
Human Papillomavirus (HPV) Associated Cancer – Dormant Projects (Contd..1), H2 2016 163

Get this report @ https://www.wiseguyreports.com/checkout?currency=one_user-USD&report_id=685904

 

Contact US:

NORAH TRENT

Partner Relations & Marketing Manager

sales@wiseguyreports.com

Ph: +1-646-845-9349 (US)

Ph: +44 208 133 9349 (UK)

Report abuse

Comments

Your Comments
Question   Razz  Sad   Evil  Exclaim  Smile  Redface  Biggrin  Surprised  Eek   Confused   Cool  LOL   Mad   Twisted  Rolleyes   Wink  Idea  Arrow  Neutral  Cry   Mr. Green

Top Stories
Recent Stories

Register

Newsletter

Email this story
Email this story

If you really want to ban this commenter, please write down the reason:

If you really want to disable all recommended stories, click on OK button. After that, you will be redirect to your options page.